Litcius/Paper detail

Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial

Bruno François, Xavier Wittebole, Ricard Ferrer, Jean‐Paul Mira, Thierry Dugernier, Sébastien Gibot, Marc Derive, Aurélie Olivier, Valérie Cuvier, Stephan Witte, Peter Pickkers, François Vandenhende, Jean–Jacques Garaud, Miguel Sánchez, Margarita Salcedo‐Magguilli, Pierre‐François Laterre

2020Intensive Care Medicine71 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePharmacodynamicsSeptic shockPlaceboAdverse effectPharmacokineticsRandomized controlled trialSOFA scorePopulationInternal medicineSepsisAnesthesiaClinical endpointClinical trialAlternative medicineEnvironmental healthPathologyInflammation biomarkers and pathwaysWhipple's Disease and InterleukinsMangiferin and Mango Extracts
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial | Litcius